复星、华润、天士力等资产大挪移暗藏怎样的资本棋局?

医药经济报
15 Apr

4月13日,博雅生物发布公告称,拟通过上海联合产权交易所挂牌转让其子公司江西博雅欣和制药有限公司(以下简称“博雅欣和”)80%的股权,首次挂牌金额为2.13亿元。公开资料显示,博雅欣和主营业务为抗感染类、糖尿病类、心脑血管类药品的研发、生产和销售,股权转让完成后,公司持有博雅欣和10.6869%股权,公司全资子公司江西博雅医药投资有限公司持有博雅欣和9.3131%股权,博雅欣和将不再纳入公司的合并...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10